Held by 4 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $40.4M Position in Oruka Therapeutics Avoro Capital's entry into ORKA signals confidence in the company's pipeline, most notably ORK-001 for localized scleroderma, which completed a Phase 2b trial in 2023.
AI analyst context — unlock full analysis
# Signal Note: Perceptive Advisors Initiates $44.8M Position in ORKA Edelman's entry into Oruka signals conviction in the company's lead program, ORK-0119, a Phase 2b OKT3-based immunotherapy for moderate-to-severe atopic dermatitis—a competitive space but one with potential for differentiation via oral dosing. The 1.5M share stake (substantial for a $~400M market cap biotech) suggests confidence in near-term data readouts; timing and efficacy relative to existing agents (dupilumab, JAK inhibitors) will be key catalysts. Edelman's track record on clinical-stage bets warrants attention to clinical progress over the next 12-18 months.
+ 2 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial